Molecular Formula | C8H4N4O6 |
Molar Mass | 252.14 |
Density | 1.6919 (rough estimate) |
Melting Point | >300°C |
Boling Point | 395.32°C (rough estimate) |
Solubility | Soluble in DMSO |
Appearance | Pale yellow solid. |
Color | Off-White to Light Yellow |
pKa | 7.68±0.20(Predicted) |
Storage Condition | Sealed in dry,2-8°C |
Stability | Store in freezer at -20°C |
Refractive Index | 1.6700 (estimate) |
In vitro study | DNQX selectively depolarizes thalamic reticular nucleus (TRN) neurons. |
In vivo study | DNQX, a specific AMPA receptor antagonist, given as either a 5 mg/kg or 10 mg/kg intraperitoneal dose or into the lateral cerebral ventricle (5 μl of 0.5 mg/ml) significantly diminished PCP (40 mg/kg) and ketamine (80, 100, 120 mg/kg) hsp70 induction in the posterior cingulate and retrosplenial cortex. |
WGK Germany | 3 |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 3.966 ml | 19.83 ml | 39.661 ml |
5 mM | 0.793 ml | 3.966 ml | 7.932 ml |
10 mM | 0.397 ml | 1.983 ml | 3.966 ml |
5 mM | 0.079 ml | 0.397 ml | 0.793 ml |
biological activity | DNQX (FG 9041), is a quinoxaline derivative, is a selective, highly competitive non-NMDA glutamate receptor (non-NMDA glutamate receptor) antagonists (IC50 of 0.5, 2 and 40 μm for AMPA, kainate and NMDA receptors, respectively). |
Target | AMPA receptor. |